Taken together, these observations indicate that the combination of FGFRi and Akti is necessary to completely abolish the growth-stimulatory pathways in FGFR1-overexpressing EGFR-TKI-resistant NSCLC cells leading to the observed decreased cell growth and proliferation. This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.